Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AZD7762 + Ixazomib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD7762||AZD-7762||CHK Inhibitor (Pan) 2||AZD7762 is an ATP-competitive CHK1/CHK2 inhibitor, which abrogates DNA damage-induced cell cycle checkpoints, and demonstrates antitumor activity when administered in combination with DNA-damaging agents (PMID: 18790776, PMID: 32335582, PMID: 31372095).|
|Ixazomib||Ninlaro||MLN9708||Ninlaro (ixazomib) inhibits proteosome activity, resulting in accumulation of misfolded proteins, inhibition of pathway signaling, and potentially leading to cell death (PMID: 20160034). Ninlaro (ixazomib) in combination with Revlimid (lenalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received at least one prior therapy (FDA.gov)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|